Search results
Results from the WOW.Com Content Network
Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.
AOL latest headlines, entertainment, sports, articles for business, health and world news.
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
The U.S. government on Tuesday released a list of 10 prescription medicines that will be subject to the first-ever price negotiations by the Medicare health program that covers Americans aged 65 ...
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
ELIQUIS ® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During ...
ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...
Stay updated with breaking news, politics, sports, and the latest headlines on AOL.com.